SAN FRANCISCO, Oct. 31, 2017 -- Velano Vascular today announced that it was named the ABBY Platinum Award winner at the 18th Annual Adaptive Business Leaders (ABL) Innovations in Healthcare event in Long Beach, CA for its PIVO blood draw technology. Velano Vascular was one of nine presenting finalists.
The ABBY Awards recognize and celebrate organizations which have brought to market innovative approaches to the delivery of healthcare, medical devices, diagnostics, healthcare IT, and digital health technologies that are dramatically reducing the cost of quality healthcare. Past ABBY and “Leadership in Innovation” award winners include Kaiser Permanente; Sutter Health; Masimo Corporation; FoxHollow Technologies; Daniel Kraft, MD, Founder of IntelliMedicine; and Steve Case, Chairman & CEO, Revolution Health Group.
Velano Vascular’s PIVO procedure enables consistent blood draws from indwelling peripheral IV lines. This innovative vascular access practice aims to reduce hospitals’ reliance on repeat needle sticks and central line access for blood draws. It also seeks to provide a more compassionate care experience for patients, a safer environment for caregivers, and a more financially responsible alternative for health systems. The device is in use at a number of leading health systems across the U.S. The FDA-cleared PIVO device is the first commercially available solution in the company’s planned family of vascular access technologies.
“We are honored to receive a prestigious ABBY award; it’s a tremendous validation of our approach to innovation and journey to commercialization,” said Velano Vascular Chief Executive Eric M. Stone. “Nearly all of us will spend time in a hospital at some point in our lives, and when we do, we’ll have our blood drawn. PIVO is on the path to becoming an actual ‘standard’ of care for each and every one of us and our loved ones.”
To learn more about Velano Vascular and PIVO, visit http://www.velanovascular.com.
About Velano Vascular
Velano Vascular is committed to reducing the pain, risk, and inefficiencies of vascular access and blood collection practices. Velano Vascular’s PIVO device enables blood draws from Peripheral IV catheters, aiming to enable more compassionate care for hospital inpatients, a safer practice for caregivers, and a more financially responsible alternative for health systems. Velano Vascular is backed by First Round Capital, Griffin Hospital, Kapor Capital, Safeguard Scientifics, Sutter Health, The Children’s Hospital of Philadelphia (CHOP), White Owl Capital, and a number of health-industry veterans. Company collaborators include several of the leading hospital systems in the United States. More information is available at www.velanovascular.com and @velanovascular.
For Press:
Michael Azzano
Cosmo PR for Velano Vascular
415/596-1978
[email protected]


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



